Ex Vivo Models for Studies at the Intersection of HIV and Addictive Substance Use (R01 Clinical Trial Not Allowed)
ID: 357939Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357939

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-074.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for research focused on the neuroimmune mechanisms linking HIV and addictive substance use, specifically targeting HIV-associated neurological disorders (HAND). This grant aims to support innovative projects utilizing advanced ex vivo models derived from human induced pluripotent stem cells (hiPSC) to investigate how addictive substances influence HAND and HIV pathology, with an emphasis on cellular interactions, neurodegeneration, and inflammatory responses in the brain. The total funding available for this initiative is $2 million, and eligible applicants include educational institutions, nonprofits, government agencies, and foreign organizations. Applications are due by July 13, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found in the full announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-074.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-25-074-Full-Announcement.html
    RFA-DA-25-074.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity for research on the neuroimmune mechanisms connecting HIV and addictive substance use, specifically targeting HIV-associated neurological disorders (HAND). The funding, amounting to $2 million, aims to support innovative projects using advanced ex vivo models derived from human induced pluripotent stem cells (hiPSC). Researchers are invited to explore how addictive substances affect HAND and HIV pathology, focusing on cellular interactions, neurodegeneration, and inflammatory responses in the brain. The expected proposals must emphasize the use of relevant human cell models and study various addictive substances’ impacts. Eligible applicants include educational institutions, nonprofits, government agencies, and foreign organizations, with applications due by July 13, 2025. The research is expected to enhance understanding of HAND and develop new approaches for treatment and intervention. NIH will review applications based on the scientific merit and significance of the research contributions, highlighting their potential to address critical gaps in the field. Overall, this funding initiative aims to advance knowledge in substance use disorders and improve patient outcomes for those living with HIV.
    Similar Opportunities
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use" (RFA-DA-25-069). This initiative aims to support research that elucidates the mechanisms of inflammasome activation related to neurocognitive disorders in individuals affected by HIV and substance use disorders (SUDs), focusing on identifying molecular markers and understanding the inflammatory responses triggered by these conditions. The program is significant for developing new therapeutic tools that could enhance clinical outcomes for affected populations. Up to four grants, totaling $2 million, will be awarded, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for detailed application instructions.
    Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV," aimed at exploring the interactions between HIV-infected microglia and substance use disorder. The objective is to generate specific microglial protein profiles and interaction networks to understand how these factors contribute to neuropathologies associated with both conditions, utilizing innovative protein profiling techniques across two study phases: R61 for analytical methods and R33 for in vivo models. This funding opportunity is significant for advancing research in health, with a total funding amount of $2.5 million available for 3-6 awards by fiscal year 2025. Interested applicants must submit their proposals by August 14, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
    Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Microglial Pathophysiology in Comorbid Substance Use Disorder (SUD) and HIV (R61/R33 Clinical Trial Not Allowed)." This initiative aims to investigate the protein interaction networks in HIV-infected microglia and their implications for cellular signaling alterations associated with the coexistence of HIV and SUD, structured in a two-phase approach focusing on both quantitative analytics and in vivo models. The funding, anticipated to be approximately $2.5 million for FY 2026, will support 3-6 awards, with applications opening on July 14, 2025, and a submission deadline of August 14, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at exploring the role of inflammasomes in the context of HIV infection and substance use disorders. This R21 exploratory grant encourages research into the mechanisms of inflammasome activation and their association with neurocognitive disorders in individuals affected by HIV and substance use, with a focus on identifying molecular markers and potential therapeutic innovations. The total funding available is up to $2 million over two years, with applications opening on February 13, 2024, and a submission deadline of March 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.